Country for PR: China
Contributor: PR Newswire Asia (China)
Thursday, June 02 2022 - 15:34
AsiaNet
Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future
NANJING, China, June 2, 2022 /PRNewswire-AsiaNet/--

Vazyme, China's leading biotechnology company, has recently released its 2021 
annual report, revealing that the company has maintained a steady and solid 
growth throughout the past year. The report shows that it has achieved $289 
million in operating income with an increase of 19.44% year-on-year. The 
company's R&D investment reached $36 million, up 83.47%, representing 12.33% of 
its total operating income.

"The year 2022 is still full of opportunities and challenges. We will continue 
to strengthen care technology based on the protein technology platform. Vazyme 
has been dedicated to our mission 'Science and Technology Make a Healthier 
Life' to focus on technology innovation and continuously expand the application 
fields of care technologies in life science, biomedicine, in vitro diagnostics, 
animal health and synthetic biology in human health. We have been holding 
ourselves to pursue the highest standards in quality of products and services 
for our customers and partners. Our global business network and operations make 
sure we could be close to the local markets, and more importantly, to do as 
much it can to meet the unmet customers' needs", said Cao Lin, chairman and 
founder of Vazyme.

This year also marks the Vazyme's 10th anniversary. Moving forward, the company 
plans to ramp up efforts in R&D and innovation, continuously upgrade and 
transform its core technologies, and expand business in new sectors. As one of 
the few R&D-focused biotech company in China, Vazyme holds a longstanding 
commitment in technology innovation. Over 2000 papers have been published by 
Vazyme in top academic journals worldwide, including more than 260 in 
CNS(stands for Cell, Nature, Science). By 2022, it has some 3000 employees and 
27% of that are in the R&D team.

"Looking ahead, we will make further inroads in our key businesses and expand 
into new domains. I believe the market demand for COVID-19 and other related 
detection materials and products will continue to be strong. During the 
pandemic, China has remained one of the largest supplier for COVID-19 detection 
products." said Cao. In addition to pandemic-induced detection businesses, 
other regular detection products will be further developed, according to Cao. 
"When the prevention and control of the pandemic become regular, there will be 
new demands for detection products. In the future we will focus on the 
development of that," added Cao.

Vazyme can not only provide COVID-19 and other related detection materials and 
products, but only offer various products and solutions in life-science 
industry for universities, laboratories, and related R&D centers, such as 
scientific research reagents, NGS Library Prep Kits and molecular diagnostics 
solutions. Currently, Vazyme has over 200 kinds of genetic engineering 
recombinases, more than 1,000 kinds of high-performance antigens, monoclonal 
antibodies, and other key raw materials, in addition to over 600 finished 
products.

As Vazyme's 10th anniversary slogan "Together for a Better Future", Vazyme aims 
to get close to its partners for a better future. In the future, Vazyme will 
provide better products and solutions, contribute to improve R&D efficiency for 
its partners, realize more scientific breakthroughs and dedicating to the 
mission "Science and Technology Make a Healthier Life".

SOURCE: Vazyme

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=422623

   Caption: Vazyme

Attachments
image-1.jpg
Translations

Japanese